Date of Document: June 4, 2023
CURRICULUM VITAE

Aaron Winn PhD
Associate Professor
Department of School of Pharmacy Administration
Division of Administration

OFFICE ADDRESS:
Medical Education Building
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
2003 - 2007 Economics, University of Illinois at Chicago, Chicago, IL
2007 - 2009 MPP, University of Chicago, Chicago, IL
2013 - 2017 PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC

FACULTY APPOINTMENTS:
09/2017 - 06/2022 Assistant Professor, Clinical Sciences, School of Pharmacy, Medical College of Wisconsin
07/2022 - 09/2022 Visiting Scholar, Health Economics Research Centre, University of Oxford
07/2022 - Present Associate Professor, Clinical Sciences, School of Pharmacy, Medical College of Wisconsin

ADMINISTRATIVE APPOINTMENTS:
2022 - Present Director of Analytics and Assessment, School of Pharmacy

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
2017 - 2019 Course Developer and Director, PHAR 550: Health Systems and Patient Safety, School of Pharmacy, Medical College of Wisconsin, Milwaukee, WI
2018 - Present Course Developer and Director, PHAR 551: Evidence Based Practice, School of Pharmacy, Medical College of Wisconsin, Milwaukee, WI
2018 - Present Course Developer and Director, PHAR 552: Population Health, School of Pharmacy, Medical College of Wisconsin, Milwaukee, WI
2021 - Present Course Director, PUCH 19925: Introduction to Statistical Analysis Using Stata, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI

AWARDS AND HONORS:
2013 - 2017 Doctoral Fellowship, Royster Society of Fellows
2016 Student Travel Grant, Lineberger Cancer Center, University of North Carolina, Chapel Hill
2017 Best Abstract, AcademyHealth
2019 Highest Quality Peer Reviewer, Journal of Managed Care and Specialty Pharmacy
2019 Cost Effectiveness Analysis Registry Paper of the Year Award, The Tufts Medical Center, Center for the Evaluation of Value of Risk in Health
2020 Ronald D. Mann Best Paper Award Honorable Mention, International Society for Pharmacoepidemiology
2021 Graduate School Outstanding Educator Award, Medical College of Wisconsin
2021 Presentation Selected as "Best of ADA" , American Diabetes Association

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
2015 - Present Journal of Clinical Oncology
2015 - Present American Journal of Preventative Medicine
2016 - Present Annals of Internal Medicine
2016 - 2017 North Carolina Journal of Medicine
2017 - Present Journal of Managed Care and Specialty Pharmacy
2017 - Present Open Forum Infectious Diseases
2017 - Present Clinical Breast Cancer
2018 - Present Alzheimer's & Dementia
2018 - Present Journal of the National Cancer Institute
2018 - Present Pharmacoepidemiology and Drug Safety
2018 - Present Cancer Causes & Control
2018 - Present The American Journal of Managed Care
2018 - Present The Gerontologist
2018 - Present Cancer
2019 - Present Value in Health
2019 - Present Journal of General Internal Medicine
2019 - Present American Journal of Preventive Medicine
2019 - Present Research in Social and Administrative Pharmacy
2019 - Present Journal of the American Pharmacists Association
2019 - Present Journal of the National Cancer Institute - Cancer Spectrum
2020 - Present Clinical Epidemiology
2020 - Present Patient Preference and Adherence
2020 - Present Journal of the American Medical Informatics Association
2021 - Present Journal of Medical Economics
2022 - Present Applied Economics

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2020 - Present Member, Advisory Board, Pharmacy Practice Enhancement and Action Research Link (PearlRx)

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2020 - Present Member, ESAS Nominations/Awards Committee, APhA
2022 - Present Member, Real World Evidence Special Interest Group, International Society for Pharmacoeconomics and Outcomes Research
2023 Ad-Hoc Member, Special Emphasis Panel on Policy and AD and ADRD Healthcare Disparities: Access, Utilization, and Quality, National Institute on Aging
2023 Ad-Hoc Member, AGCD2 Chartered Review Committee, Career Development for Early Career Investigators Study Section, National Institute on Aging

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option
Source:
NHLBI 1OT3HL151434
Role:
Investigator
PI:
Ramsey
Dates:
01/07/2019 - 06/30/2022
Direct Funds:
$727,500 (Using data from multiple large claims databases (Medicare, Medicaid, and MarketScan), I, with input from other investigators, developed of a mathematical model of the relationships between patient demographics, treatments and sickle cell disease related outcomes. Moreover, we incorporate the impact of sickle cell events on patients’ quality of life and health care costs. Using this model, we will examine the costs and value of new treatments for patient with sickle cell disease.)
  
Title:
Understanding and addressing health disparities in Wisconsin through statewide partnerships
Source:
Advancing Healthier Wisconsin
Role:
Investigator
PI:
Neuner
Dates:
07/01/2021 - 06/30/2024
Direct Funds:
$1,500,000 (This project will 1) develop reports on populations with the greatest disparities in access to care, quality of care, healthcare use, and health outcomes in Wisconsin over time 2) build and evaluate statewide capacity to enhance health improvement strategies with best practices that simultaneously reduce disparities, and 3) Facilitate partnerships to develop and amplify research to target disparities that lack evidence-based interventions. As an investigator and methodologist for this project, my role focuses on accurate study design and accurate measurement of quality of care using administrative data sources. )
  
Title:
Bridging Community-based Continence Promotion and Primary Care
Source:
AHRQ
Role:
Investigator
PI:
Brown, Neuner, and Flynn (Co-PIs)
Dates:
02/01/2022 - 01/31/2025
Direct Funds:
$2,999,558 (This project aims to evaluate the effectiveness of a primary care based practice facilitation effort either used alone or in combination with community partnerships to promote use of evidence based practices for non-surgical intervention for urinary incontinence. As an investigator, I will lead the economic analysis to determine the value of the services provided.)
  
Title:
Understanding and Addressing Opioid and Benzodiazepine Co-prescribing among Older Adults with Cancer
Source:
NIA R21AG072688
Role:
PI
PI:
Winn and Check
Dates:
03/01/2022 - 02/28/2024
Direct Funds:
$466,440 (This study will characterize patterns of opioid and benzodiazepine co-prescribing among older adults diagnosed with breast, colorectal, or lung cancer and examine the risks of avoidable harms associated with opioid and benzodiazepine co-prescribing. As the co-PI, will be responsible for the overall execution of the project, with particular focus on the quantitative analysis. I will oversee the research design, planning, analyses for all aspects of the quantitative analysis (Aims 1 and 2).)
  
Title:
Understanding the Importance of Industry Relationships for Cancer Care Quality, Outcomes, and Costs
Source:
National Cancer Institute
Role:
Investigator
PI:
Mitchell (Memorial Sloan Kettering)
Dates:
09/2022 - 08/2027
Direct Funds:
$2,138,965 (Personal payments from the pharmaceutical industry to US physicians are common and influence physician prescribing. Approximately 80% of medical oncologists receive personal payments from industry each year, with a mean of over $5,500 per physician. This grant will assess whether receipt of industry payments by physicians is associated with the likelihood that they deliver the guideline-preferred treatment for each patient and established forms of low-value care. Additionally, we will assess the association between industry payments and patient outcomes and costs of care. As an investigator and methodologist for this project, I will supervise the data analysts and lead the statistical analysis.)
  
Non-Peer Review
Title:
Evaluation of Wisconsin’s SeniorCare Prescription Drug Program
Source:
Wisconsin Department of Health Services
Role:
Investigator
PI:
Look
Dates:
2021 - 2026
  
Prior
Peer Review
Title:
Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
Source:
NCI 1R01CA184798
Role:
Investigator
PI:
Flynn and Atallah
Dates:
01/01/2015 - 08/31/2021
Direct Funds:
$3,345,984 (The Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop TKIs) study discontinued TKI therapy in 170 willing and eligible CML patients and monitored them closely for 3 years to characterize the patient factors associated with CML recurrence, described patient-reported health status changes after TKI discontinuation, and explored patient decision making regarding discontinuation with monitoring. In this study, I examined the quality of life impact, as measured using a quality adjusted life year, developed a simulation model with forecasted the health care savings of stopping TKI and overall value of stopping TKIs. )
  
Title:
Using Big Data Informatics to Improve Care of Women with Advance Breast Cancer
Source:
Advancing a Healthier Wisconsin and the CTSI
Role:
PI
PI:
Winn
Dates:
08/01/2018 - 07/31/2020
Direct Funds:
$250,000 (This study examined the use of CDK4/6 inhibitors among women with advanced breast cancer and explored patient factors that influenced utilization. Among post-menopausal women with estrogen or progesterone receptor- positive advanced breast cancer, we found substantial racial disparities in use of CDK4/6 inhibitors.)
  
Title:
Predicting and Reducing Future Health Disparities for U.S. Adults with Diabetes
Source:
National Institute on Minority Health and Health Disparities R01MD013420
Role:
Investigator/Methodologist
PI:
Laiteerapong (University of Chicago)
Dates:
10/19/2018 - 04/30/2022
Direct Funds:
$2,022,438 (Using data from Kaiser Permanente Northern California, a multi-ethnic, socioeconomically diverse population with diabetes (n~192,000) (16% Latino, 11% African American, 7% South Asian, 4% Chinese; 13% difficulty with English) I, with input from other investigators, developed of a mathematical model of the relationships between patient risk factors and outcomes. We are using this simulation model to forecast the long-term implications of efforts to reduce diabetes health disparities.)
  
Title:
Hearing Patient's Voice: Contextual Phenotyping of Patient Narratives and Clinical Data using ML & NLP
Source:
Clinical & Translational Science Institute
Role:
Investigator
PI:
Somai
Dates:
07/01/2020 - 06/30/2021
Direct Funds:
$50,000 (In this study, I provided input on appropriate study design. )
  
Title:
Wisconsin Exploratory Center for Interdisciplinary Research in Benign Urology. Project Title: Improving Lower Urinary Tract Symptoms through Interdisciplinary Research and Collaboration between Primary and Specialty Care
Source:
NIDDK P20 DK127511
Role:
Investigator
PI:
Flynn and Neuner
Dates:
09/15/2020 - 06/30/2022
Direct Funds:
$624,000 (The Wisconsin Exploratory Center will enhance the intellectual infrastructure of the benign genitourinary research community and foster scientific research that advances the field by bringing together members of our local community of scientists already investigating benign genitourinary diseases, recruiting experienced scientists investigating other conditions to apply their expertise and techniques to the study of benign genitourinary diseases, conducting pilot research, and supporting student research experiences and a seminar series. For this project, I have served as a epidemiological and statistical methodologist for observational research studies focused on understanding factors that improve UI care.)
  
Title:
Evaluation of a pharmacist-led immunization program to impact vaccination rates for elderly and underserved patients during the COVID-19 era
Source:
American Society of Health-System Pharmacists Foundation
Role:
Mentor
PI:
Smith
Dates:
05/01/2021 - 07/31/2022
Direct Funds:
$2,500 (Proposal for Dr. Courtney Smith, PharmD for career development to mixed-methods research. This study examines the impact of a pharmacist-led visit, coupled with interdisciplinary teamwork with other immunizing providers in order to enhance patient trust for receiving vaccinations, promote effective patient-provider communication, and encourage efficient decision-making for vaccine recommendations during the COVID-19 era. This study utilizes a qualitative, mixed-methods study in order to assess the potential benefits and opportunities for a pharmacist-led immunization program to increase pneumococcal and influenza vaccination rates.)
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Regional
Aaron N Winn, Regression Discontinuity Design, University of Wisconsin Graduate School Research Seminar, Virtual due to COVID-19, 12/03/2020
Aaron N Winn, Introduction to Propensity Scores, University of Wisconsin Graduate School Research Seminar, Virtual due to COVID-19, 12/04/2020
Aaron N Winn, Understanding and Applying Regression Discontinuity Design, University of Wisconsin Graduate School Research Seminar, Madison, WI, 12/08/2022
Aaron N Winn, Why do simulation modeling? A case study in the value of new diabetes treatments and understanding health disparities., University of Wisconsin School of Pharmacy Section of Social and Administrative Pharmacy Seminar Series, Madison, WI, 12/09/2022
Aaron N Winn, Propensity Score Analysis, University of Wisconsin Graduate School Research Seminar, Madison, WI, 12/09/2022
 
National
Aaron N Winn, The Role of Social Networks in the Receipt of Industry Payments, Health Economics Workshop at the University of Chicago, 2018
Aaron N Winn, Understanding the Role of Patient Costs In Use and Adherence to High Value Cancer Medications, Chronic Diseases & Medical Decision Making, University of Chicago, 08/2020
Aaron N Winn, The Effect of Health System Factors on Vulnerable Populations, Division of Pharmaceutical Outcomes and Policy Seminar at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy, 2020
Aaron N Winn, SGLT2is and GLP-1RAs—Equity and Value, American Diabetes Association Annual Meeting, Virtual due to COVID-19, 2021
Aaron N Winn, Understanding the Role of Patient Costs In Use and Adherence to High Value Cancer Medications, Social and Administrative Pharmacy Seminar, Minneapolis, MN, 03/03/2022
Aaron N Winn, Development and Internal Validity of the Type 2 Diabetes Outcomes Model of the US (DOMUS), Chronic Diseases & Medical Decision Making, Chicago, IL, 03/30/2022
 
International
Aaron N Winn, Development and Validation of a US Based Diabetes Model, Health Economic Research Centre Seminar, Oxford University, Oxford, UK, 07/2022
 

PEER REVIEWED WORKSHOPS/PRESENTATIONS:
Local
Winn AN, Mitchell A, Fergestrom N, Neuner JM, Trogdon J, The Role of Physician Social Networks in Receipt of Pharmaceutical Industry Payments, Milwaukee Regional Research Forum, Milwaukee, WI, 2018
 
National
Huang E, Winn AN, John P, Chin M, Meltzer D, The impact of baseline health status on the prioritization of intensive control of glucose and blood pressure levels in elderly patients with diabetes, Society for Medical Decision Making, 2008
Winn AN, John P, Sarkisian C, Meltzer D, Huang E, The Association of Expectations Regarding Aging and Diabetes-Related Utilities, American Geriatrics Society, 2009
Winn, AN, O’Grady, M, John P, Substantial Medicare Savings May Result If Insurers Cover ‘Artificial Pancreas’ Sooner For Diabetes Patients, AcademyHealth, 2011
Lin PJ, Cohen JT, Winn AN, Kent DM, Neumann PJ, Patterns of Comorbidity Clusters Among Adults with Diabetes, AcademyHealth, 2013
Olchanski N, Winn AN, Cohen JT, Neumann PJ, Abdominal Aortic Aneurysm Screening: How Many Life Years Lost From Underuse of the Medicare Screening Benefit?, AcademyHealth, 2013
Olchanski N, Winn AN, Cohen JT, Neumann PJ, Abdominal Aortic Aneurysm Screening: The Impact of the SAAAVE Act of 2007, AcademyHealth, 2013
Shah G, Winn AN, Cohen J, Lin P, Parsons S, Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database., American Society of Clinical Oncology, 2014
Shah G, Winn AN, Cohen J, Lin P, Parsons S., Cost-Implications Of Comorbidity For Autologous Hematopoietic Stem Cell Transplantation (Auto HSCT) In Elderly Patients With Multiple Myeloma (MM) Using The SEER-Medicare Database, American Society of Hematology, 2014
Winn AN, Dusetzina SB, Importance of Capturing Longitudinal Adherence Trajectories: Mortality and Adherence to Hormonal Therapy Among Women with Breast Cancer, AcademyHealth, 2015
Olchanski N, Winn AN, Zhang Y, The Development, Calibration, and Validation of the US Population Health Microsimulation Model, Society of Medical Decision Making, 2016
Winn AN, Dusetzina SB, Factors Associated with Tyrosine Kinase Inhibitors Initiation and Adherence among Medicare Beneficiaries with Chronic Myeloid Leukemia, AcademyHealth, 2016
Olchanski N, Winn AN, Zhang Y, Cohen J, A Simulation Approach to Population Health: The Development and Validation of the US Population Health Microsimulation Model, AcademyHealth, 2016
Shah GL, Winn AN, Lin PJ, Kumar AJ, Parsons SK, Comparison of Survival and Costs of Rituximab-Based Chemotherapy for Initial Therapy of Follicular Lymphoma in Elderly Patients, American Society of Hematology, 2016
Dusetzina SB, Huskamp H, Winn AN, Basch E, Keating N, The Impact of State Chemotherapy Laws on Use and Spending for Oral Chemotherapy, AcademyHealth, 2016
Shah GL, Winn AN, Lin PJ, Kumar AJ, Parsons SK, The Utility of the Charlson Comorbidity Index in Predicting Use of Treatment and Survival in Older Lymphoma Patients, American Society of Hematology, 2016
Mitchell A, Winn AN, and Dusetzina SB, Pharmaceutical Industry Payments and Physician Drug Selection in Oncology, AcademyHealth, 2017
Winn AN, Dusetzina SB, Winn AN, Dusetzina SB. Paying More for the Same Care: Comparing Physician Office and Hospital Outpatient Department Spending for Infused Chemotherapy among Privately Insured Patients., AcademyHealth, 2017
Mitchell A, Winn AN, and Dusetzina SB, Pharmaceutical Industry Payments and Physician Drug Selection in Oncology, American Society of Clinical Oncology, 2017
Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB, Association between Chemotherapy Provider Competition and Access, Cost and Quality of Care for Medicare Beneficiaries with Cancer, Annual Conference of the American Society of Health Economist (ASHEcon), Atlanta, GA, 2018
Roberts A, Neuner, JM, Fergestrom N, Winn AN, New onset persistent opioid use among older adult breast cancer survivors, American Pharmacists Association (APhA) Annual Meeting & Exposition, Seattle, WA, 2019
Winn AN, Fergestrom NM, Neuner JM, The Impact of Reduced Copays on Primary and Secondary Adherence to Hormonal Therapy for Older Breast Cancer Patients: Multi-State Analysis, 41st Annual Meeting of the Society for Medical Decision Making, Portland, OR, 2019
Winn AN, Karter AJ, Staab EM, Liu J, Wan W, Skandari R, Knitter AC, Moffet HM, Miller DR, Peek ME, Huang ES, Laiteerapong N, Racial Difference in Diabetes Medication Initiation, American Diabetes Association Annual Meeting, Virtual, 2020
Choi J, Winn AN, Skandari R, Franco M, Staab EM, Huang ES, Wan W, Philipson L, Laiteerapong N, US Cost-Effectiveness of First-Line Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2I) for Patients With Type 2 Diabetes, Society of General Internal Medicine 2021 Annual Meeting, Virtual, 2021
 
International
Cangelosi MJ, Zhong Y, Winn AN, Chambers JD, Value-Based Insurance Desing Informed By Government Research: A Case Study of Osteoporosis Fractures, International Society for Pharmacoeconomics and Outcomes Research, 2013
Chambers JD, Pyo J, Winn A, Neumann PJ, A Systematic Review of the Network Meta-Analysis Literature, International Society for Pharmacoeconomics and Outcomes Research, 2013
Lin PJ, Cohen JT, Winn AN, Kent DM, Neumann PJ., Patterns of Comorbidity Clusters Among Adults with Diabetes, International Society for Pharmacoeconomics and Outcomes Research, 2013
Lin P, Olchanski N, Winn AN, Lang K, Using EMR Data for Conducting Retrospective Studies: Opportunities and Pitfalls, International Society for Pharmacoeconomics and Outcomes Research, 2013
Winn AN, Neumann PJ, Cost-Effectiveness of FDA-Approved Cancer Drugs Since 2000, of International Society for Pharmacoeconomics and Outcomes Research, 2013
Olchanski N, Winn AN, Cohen JT, Neumann PJ, Abdominal Aortic Aneurysm Screening: How Many Life Years Lost From Underuse of the Medicare Screening Benefit?, International Meeting of International Society for Pharmacoeconomics and Outcomes Research, 2013
Olchanski N, Zhong Y, Winn AN, Terrin N, Cohen JT, Neumann PJ, Population Health Model: Projecting Health Trajectory of the Massachusetts Population, International Society for Pharmacoeconomics and Outcomes Research, 2014
Winn AN, Lin P, Cohen J, Parsons S, Cost-effectiveness Analysis of Innovation in Hematologic Malignancies, International Society for Pharmacoeconomics and Outcomes Research, 2014
Saret C, Winn AN, Cohen J, Lin P, Shah G, Parsons S, Value of Innovation in leukemia, Lymphoma and Myeloma: A Systematic Review, International Society for Pharmacoeconomics and Outcomes Research, 2014
Zhong Y, Lin PJ, Winn AN, Cohen JT, Neumann PJ, Cost-utility Analyses in Diabetes: A Systematic Review and Potential Gains from Using Economic Evidence, International Society for Pharmacoeconomics and Outcomes Research, 2014
Dusetzina SB, Winn AN, Taking Medication Adherence Personally: What Does Prior Adherence Tell Us about Future Adherence?, International Conference on Pharmacoepidemology and Therapeutic Risk Management, 2015
Winn AN, Dusetzina SB, Improving Adherence Measurement for Applied Pharmacoepidemiology: Estimating the Association between Endocrine Therapy Adherence and Mortality among Women with Breast Cancer, International Conference on Pharmacoepidemology and Therapeutic Risk Management, 2015
Winn AN, Dusetzina S, Multi-State Models – A Complimentary Approach to Group Based Trajectory Models, International Conference on Pharmacoepidemology and Therapeutic Risk Management, 2016
Kumar AJ, Winn AN, Lin PJ, Shah GL, Parsons SK, . Enrollment Patterns for Hospice and Cost of End-of-Life Care Among Elderly Patients with Diffuse Large B-cell Lymphoma: A SEER-Medicare Analysis, International Meeting of International Society for Pharmacoeconomics and Outcomes Research, 2016
Kumar AJ, Winn AN, Lin PJ, Shah GL, Parsons SK, Cost-Effectiveness of Rituximab-based Chemotherapy Combinations for the Initial Therapy of Follicular Lymphoma, International Society for Pharmacoeconomics and Outcomes Research, 2016
Winn AN, Fergestrom N, Neuner JM, Using Group Based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects: the Case Study of Generic Hormonal Therapy for Women With Breast Cancer, International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic, 2018
Winn AN, Fergestrom N, Neuner JM, Trogdon J, The Role Of Physician Social Networks in Receipt of Pharmaceutical Payments, International Health Economics Association World Congress, Basel, Switzerland, 2019
Winn AN, Fergestrom NM, Nuener JM, The Impact of Reduced Copay for Hormonal Therapy on Primary and Secondary NonAdherence for Breast Cancer Medicare Patients, 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, 2019
 

COMMITTEE SERVICE:
Medical College of Wisconsin
2017 - 2018 Member, Assessment, School of Pharmacy
2017 - 2019 Member, Faculty Council
2018 - Present Chair, Assessment, School of Pharmacy
2019 Member, Search Committee, School of Pharmacy
2019 - Present Member, Accreditation Council for Pharmacy Education (ACPE) Self-Study Committee, School of Pharmacy
2020 Member, Search Committee, Medical College of Wisconsin
2021 - Present Member, Student Wellness and Assessment Task Force, School of Pharmacy
2021 - Present Member, Awards and Honors, School of Pharmacy
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Graduate Student Education
2018 - Present PUCH 18223: Public Health Policy, 1 lecture titled, "Pharmacoeconomics and Drug Policy"
2018 - Present PUCH 19229A, Survey Research Methods, 1 lecture titled, "Using Stata: Tips and Tricks"
2021 - Present PUCH 19925: Introduction to Statistical Analysis Using Stata, Course Director and Instructor (48 Contact Hours)
 
Pharmacy Student Education
2017 - Present PHAR 552: Population Health, Course Director and Instructor (21 Contact Hours)
2017 - Present PHAR 551: Evidence Based Practice, Course Director and Instructor (20 Contact Hours)
2018 - 2019 PHAR 550: Health Systems and Patient Safety, Course Director and Instructor (11 Contact Hours)
2018 - Present PHAR 530: Patient Care Lab I - Lab Lead - Parts of an Article
2020 - Present PHAR 533: Patient Care Lab IV - Lab Lead - Introduction to Journal Club
 

PROGRAMMATIC DEVELOPMENTS:
Educational Programs
Faculty
2020 - 2021 Lead the creation of a new strategic plan for the School of Pharmacy
 
Research Programs
09/2018 - 08/2020 CTSI of Southeast Wisconsin, Clinical Research Scholars Program
 
 
 

SELECTED MEDIA COVERAGE:
Zand, B., Why are cancer drugs more expensive than ever?, in Houston Chronicle. 2018: Houston, TX.
Allen, A. For Highland Park man, why did a single shot of a very old cancer drug cost $38,398? Chicago Sun Times. Oct 28, 2022 Available at: https://chicago.suntimes.com/consumer-affairs/2022/10/28/23427268/healthcare-bills-billing-paul-hinds-josie-tenore-highland-park-university-chicago-medicine-lupron
Miller, J., Many women with breast cancer, limited pharmacy access forgo flu shot, in Healio. 2021.
Cohen, E.K., Aaron. Bayer paid doctors millions for questionable birth control device. CNN. 2018; Available from: https://www.cnn.com/2018/07/27/health/essure-bayer-doctor-payments-eprise/index.html?no-st=1532986280.
Schroeder, M., How to Better Manage Diabetes – and Save Money Doing It, in US News and World Report. 2018.
Weintraub, A., Laws To Control Cancer Drug Costs Don't Help Patients With Highest Expenses, in Forbes. 2017. https://www.forbes.com/sites/arleneweintraub/2017/11/09/laws-to-control-cancer-drug-costs-dont-help-patients-with-highest-expenses/?sh=3f37c9797aa6
Dodge, B., We got an exclusive look at the presentation that convinced 3 rival firms to invest $37.5 million in a hot healthcare startup that's using AI to keep patients out of the emergency room, in Business Insider. 2020: New York City, NY.
Carrol, L., Online triage tool may help patients decide if they need immediate care, in Reuters. 2019.
Worcester, S., Beyond Misuse: AEs and Opioids in Older Cancer Survivors, in Medscape. 2020.
Meara, P. One Type Of Cancer Is Killing Black Women At Record-High Rates. White women are less likely to die from the same condition. 2019; BET. Available from: https://www.bet.com/article/1qv8h9/a-type-of-cancer-is-killing-black-women-at-record-high-rates.
Johnston, C., Study Gives Mixed Reviews on Laws to Equalize Cancer Patients Out of Pocket Costs, in Washington Post. 2017.
Ornstein, C.W., Tracy; Grochowski Jones, Ryann, Across the U.S., over 700 doctors were paid more than a million dollars by drug and medical-device companies since 2014, in The Philadelphia Inquirer. 2019: Philadelphia.
Wetsman, N. Google’s new tool will identify skin conditions — what will people do with that information? The Verge. 2021. https://www.theverge.com/2021/5/24/22451361/google-skin-condition-dermatology-symptom-checker
Szabo, L. As Drug Costs Soar, People Delay Or Skip Cancer Treatments. NPR. 2017; Available from: https://www.npr.org/sections/health-shots/2017/03/15/520110742/as-drug-costs-soar-people-delay-or-skip-cancer-treatments.
Ornstein, C.W., Tracy; Grochowski Jones, Ryann, Across the U.S., over 700 doctors were paid more than a million dollars by drug and medical-device companies since 2014, in The Philadelphia Inquirer. 2019: Philadelphia.


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010 Jun;33(6):1269-74. PMCID: PMC2875436
2. Greeley SA, John PM, Winn AN, Ornelas J, Lipton RB, Philipson LH, Bell GI, Huang ES. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care. 2011 Mar;34(3):622-7. PMCID: PMC3041194
3. Lee JM, Rhee K, O'grady MJ, Basu A, Winn A, John P, Meltzer DO, Kollman C, Laffel LM, Lawrence JM, Tamborlane WV, Wysocki T, Xing D, Huang ES, JDRF Continuous Glucose Monitoring Study Group. Health utilities for children and adults with type 1 diabetes. Med Care. 2011 Oct;49(10):924-31. PMCID: PMC3210197
4. O'Grady MJ, John P, Winn A. Substantial Medicare savings may result if insurers cover 'artificial pancreas' sooner for diabetes patients. Health Aff (Millwood). 2012 Aug;31(8):1822-9.
5. Naylor RN, John PM, Winn AN, Carmody D, Greeley SA, Philipson LH, Bell GI, Huang ES. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014;37(1):202-9. PMCID: PMC3867988
6. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014 Feb 01;32(4):306-11.
7. Olchanski N, Winn A, Cohen JT, Neumann PJ. Abdominal aortic aneurysm screening: how many life years lost from underuse of the medicare screening benefit? J Gen Intern Med. 2014 Aug;29(8):1155-61. PMCID: PMC4099445
8. Chambers JD, Winn A, Zhong Y, Olchanski N, Cangelosi MJ. Potential role of network meta-analysis in value-based insurance design. Am J Manag Care. 2014 Aug;20(8):641-8.
9. Saret CJ, Winn AN, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015 Mar 19;125(12):1866-9. PMCID: PMC4366623
10. Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health. 2015 Mar;18(2):308-14.
11. Lin PJ, Kent DM, Winn A, Cohen JT, Neumann PJ. Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequences. Am J Manag Care. 2015 Jan 01;21(1):e23-34.
12. Chambers JD, Naci H, Wouters OJ, Pyo J, Gunjal S, Kennedy IR, Hoey MG, Winn A, Neumann PJ. An assessment of the methodological quality of published network meta-analyses: a systematic review. PLoS One. 2015;10(4):e0121715. PMCID: PMC4414531
13. Winn AN, Shah GL, Cohen JT, Lin PJ, Parsons SK. The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst. 2015 Aug;107(8). PMCID: PMC4554189
14. Shah GL, Winn AN, Lin PJ, Klein A, Sprague KA, Smith HP, Buchsbaum R, Cohen JT, Miller KB, Comenzo R, Parsons SK. Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant. 2015 Oct;21(10):1823-9. PMCID: PMC4933291
15. Dusetzina SB, Ellis S, Freedman RA, Conti RM, Winn AN, Chambers JD, Alexander GC, Huskamp HA, Keating NL. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. J Oncol Pract. 2015 Jul;11(4):313-8. PMCID: PMC4507391
16. Winn AN, Ekwueme DU, Guy GP Jr, Neumann PJ. Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review. Am J Prev Med. 2016 Feb;50(2):241-8. PMCID: PMC5846573
17. Lin PJ, Winn AN, Parsons SK, Neumann PJ, Weiss ES, Cohen JT. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007. Med Care. 2016 Apr;54(4):380-5.
18. Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):953-9.
19. Aarnio E, Martikainen J, Winn AN, Huupponen R, Vahtera J, Korhonen MJ. Socioeconomic Inequalities in Statin Adherence Under Universal Coverage: Does Sex Matter? Circ Cardiovasc Qual Outcomes. 2016 Nov;9(6):704-713.
20. Gennetian, L, Seshadri, R, Hess, N, Winn, AN, Goerge, R. Supplemental Nutrition Assistance Program (SNAP) Benefit Cycles and Student Disciplinary Infractions Social Service Review. 90(3): 403-433. .
21. Shah GL, Winn A, Lin PJ, Klein A, Sprague KA, Smith HP, Buchsbaum R, Cohen JT, Miller KB, Comenzo R, Parsons SK. Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. Bone Marrow Res. 2016;2016:3645623. PMCID: PMC5088316
22. Sullivan SA, Clark LH, Staley AS, Tran AQ, Winn A, Kim KH. Association between timing of cervical excision procedure to minimally invasive hysterectomy and surgical complications. Gynecol Oncol. 2017 Feb;144(2):294-298.
23. Winn AN, Keating NL, Dusetzina SB. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. J Clin Oncol. 2016 Dec 20;34(36):4323-4328. PMCID: PMC5455309
24. Doll KM, Winn AN, Goff BA. Untangling the Black-White mortality gap in endometrial cancer: a cohort simulation. Am J Obstet Gynecol. 2017 Mar;216(3):324-325.
25. Chou YT, Winn AN, Rosenstein DL, Dusetzina SB. Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):676-684. PMCID: PMC5457339
26. Jazowski SA, Winn AN. The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care. Curr Diab Rep. 2017 Jun;17(6):40.
27. Anderson C, Winn AN, Dusetzina SB, Nichols HB. Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ. J Cancer Epidemiol. 2017;2017:6091709. PMCID: PMC5615957
28. Dusetzina SB, Huskamp HA, Winn AN, Basch E, Keating NL. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. JAMA Oncol. 2018 Jun 14;4(6):e173598. PMCID: PMC6054307
29. Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, Huang ES. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 Feb 06;168(3):170-178. PMCID: PMC5989575
30. Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA Oncol. 2018 Apr 01;4(4):580-581. PMCID: PMC5885220
31. Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. 2018 Jun 01;178(6):854-856. PMCID: PMC6145757
32. Wan W, Skandari MR, Minc A, Nathan AG, Winn A, Zarei P, O'Grady M, Huang ES. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care. 2018 Jun;41(6):1227-1234. PMCID: PMC5961392
33. Wan W, Skandari MR, Minc A, Nathan AG, Zarei P, Winn AN, O'Grady M, Huang ES. Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Med Decis Making. 2018 Nov;38(8):942-953. PMCID: PMC6226055
34. Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. Urol Oncol. 2019 Feb;37(2):145-149.
35. Winn AN, Fergestrom NM, Neuner JM. Using Group-based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects: The Case Study of Generic Hormonal Therapy for Women With Breast Cancer. Med Care. 2019 Jan;57(1):85-93. PMCID: PMC6291347
36. Mitchell AP, Winn AN, Lund JL, Dusetzina SB. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. Oncologist. 2019 May;24(5):632-639. PMCID: PMC6516135
37. Doll KM, Winn AN. Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis. Am J Obstet Gynecol. 2019 Oct;221(4):318.e1-318.e9.
38. Crotty BH, Winn AN, Asan O, Nagavally S, Walker RJ, Egede LE. Clinician Encouragement and Online Health Record Usage. J Gen Intern Med. 2019 Nov;34(11):2345-2347. PMCID: PMC6848784
39. Winn AN, Maciejewski ML, Dusetzina SB. Identifying Heterogeneous Treatment Effects of Drug Policy in Quasi-experimental Settings. Current Epidemiology Reports. 2019:1-7.
40. Kochar B, Jiang Y, Winn A, Barnes EL, Martin CF, Long MD, Kappelman MD. The Early Experience With Vedolizumab in the United States. Crohns Colitis 360. 2019 Oct;1(3):otz027. PMCID: PMC6798787
41. Roberts AW, Fergestrom N, Neuner JM, Winn AN. New-onset persistent opioid use following breast cancer treatment in older adult women. Cancer. 2020 Feb 15;126(4):814-822. PMCID: PMC6994182
42. Winn AN, Somai M, Fergestrom N, Crotty BH. Association of Use of Online Symptom Checkers With Patients' Plans for Seeking Care. JAMA Netw Open. 2019 Dec 02;2(12):e1918561. PMCID: PMC6991310
43. Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Wood WA, Olszewski A, Basch E, Keating NL. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. J Natl Cancer Inst. 2020 Oct 01;112(10):1055-1062. PMCID: PMC7566334
44. Winn AN, Fergestrom NM, Pezzin LE, Laud PW, Neuner JM. The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi-state models to understand the dynamics of adherence. Pharmacoepidemiol Drug Saf. 2020 May;29(5):550-557.
45. Check DK, Winn AN, Fergestrom N, Reeder-Hayes KE, Neuner JM, Roberts AW. Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer. J Natl Cancer Inst. 2020 Jul 01;112(7):765-768. PMCID: PMC7357325
46. Holt JM, Cusatis R, Winn A, Asan O, Spanbauer C, Williams JS, Flynn KE, Somai M, Laud P, Crotty BH. The Impact of Previsit Contextual Data Collection on Patient-Provider Communication and Patient Activation: Study Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2020 Sep 23;9(9):e20309. PMCID: PMC7542405
47. Look K, Kim NH, Dague L, Winn A. Trends in a State Pharmaceutical Assistance Program for Low-income Older Adults in Wisconsin. INNOVATIONS in pharmacy. 2020 Nov 5;11(4):9.
48. Winn AN, Check DK, Farkas A, Fergestrom NM, Neuner JM, Roberts AW. Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer. JAMA Netw Open. 2020 Sep 01;3(9):e2016858. PMCID: PMC7492912
49. Look K, Kim NH, Dague L, Winn A. Trends in a State Pharmaceutical Assistance Program for Low-income Older Adults in Wisconsin. Innov Pharm. 2020;11(4). PMCID: PMC8127112
50. Williams D Jr, Lawrence J, Hong YR, Winn A. Tele-ICUs for COVID-19: A Look at National Prevalence and Characteristics of Hospitals Providing Teleintensive Care. J Rural Health. 2021 Jan;37(1):133-141. PMCID: PMC7675587
51. Farkas AH, Winn A, Pezzin LE, Fergestrom N, Laud P, Neuner JM. The Use and Concurrent Use of Side Effect Controlling Medications Among Women on Aromatase Inhibitors. J Womens Health (Larchmt). 2021 Jan;30(1):131-136. PMCID: PMC7826422
52. Seymour EK, Ruterbusch JJ, Winn AN, George JA, Beebe-Dimmer JL, Schiffer CA. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. Cancer. 2021 Jan 01;127(1):93-102.
53. Zhou Y, Beyer KMM, Laud PW, Winn AN, Pezzin LE, Nattinger AB, Neuner J. An adapted two-step floating catchment area method accounting for urban-rural differences in spatial access to pharmacies. J Pharm Health Serv Res. 2021 Mar;12(1):69-77. PMCID: PMC7938828
54. Holt JM, Cusatis R, Winn A, Asan O, Spanbauer C, Williams JS, Flynn KE, Somai M, Talsma A, Laud P, Makoul G, Crotty BH. Impact of Pre-visit Contextual Data Collection on Patient-Physician Communication and Patient Activation: a Randomized Trial. J Gen Intern Med. 2021 Nov;36(11):3321-3329. PMCID: PMC8606508
55. Holt JM, Winn A, Cusatis R, Talsma A, Crotty BH. Racial Disparities in Patient Activation: The Role of Economic Diversity. West J Nurs Res. 2021 Jun;43(6):517-529.
56. Winn AN, Mitchell AP, Fergestrom N, Neuner JM, Trogdon JG. The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments. J Gen Intern Med. 2021 Jul;36(7):1858-1866. PMCID: PMC8298740
57. Kim NH, Look KA, Dague L, Winn AN. Financial burden and medication adherence among near-poor older adults in a pharmaceutical assistance program. Res Social Adm Pharm. 2022 Mar;18(3):2517-2523.
58. Winn AN, Kelly M, Ciprut S, Walter D, Gold HT, Zeliadt SB, Sherman SE, Makarov DV. The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer. Cancer Rep (Hoboken). 2022 Feb;5(2):e1468. PMCID: PMC8842701
59. Neuner JM, Zhou Y, Fergestrom N, Winn A, Pezzin L, Laud PW, Beyer K. Pharmacy deserts and patients with breast cancer receipt of influenza vaccines. J Am Pharm Assoc (2003). 2021;61(6):e25-e31. PMCID: PMC8783974
60. Mitchell AP, Mishra A, Dey P, Curry MA, Trivedi NU, Haddadin M, Rahman MW, Winn AN, Dusetzina SB, Bach PB. Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist. 2021 Sep;26(9):771-778. PMCID: PMC8417859
61. Bakken BK, Winn AN. Clinician burnout during the COVID-19 pandemic before vaccine administration. J Am Pharm Assoc (2003). 2021;61(5):e71-e77. PMCID: PMC8056845
62. Crotty BH, Hyun N, Polovneff A, Dong Y, Decker MC, Mortensen N, Holt JM, Winn AN, Laud PW, Somai MM. Analysis of Clinician and Patient Factors and Completion of Telemedicine Appointments Using Video. JAMA Netw Open. 2021 Nov 01;4(11):e2132917. PMCID: PMC8569484
63. Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, Bolen S, Maruthur NM, Huang ES, Philipson LH, Winn AN, Thomas CC, Zeytinoglu M, Press VG, Tung EL, Gunter K, Bindon B, Jumani S, Laiteerapong N. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 Feb;37(2):415-438. PMCID: PMC8810987
64. Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, Bolen S, Maruthur NM, Huang ES, Philipson LH, Winn AN, Thomas CC, Zeytinoglu M, Press VG, Tung EL, Gunter K, Bindon B, Jumani S, Laiteerapong N. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med. 2022 Feb;37(2):439-448. PMCID: PMC8811049
65. Check DK, Avecilla RAV, Mills C, Dinan MA, Kamal AH, Murphy B, Rezk S, Winn A, Oeffinger KC. Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies. J Pain Symptom Manage. 2022 Apr;63(4):e397-e417.
66. Neuner J, Weil E, Fergestrom N, Stolley M, Kamaraju S, Oxencis C, Winn A, Laud PW, Flynn KE. Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence. J Am Pharm Assoc (2003). 2022;62(4):1321-1328.e3.
67. Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Basch E, Keating NL. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. JAMA Health Forum. 2021 May;2(5):e210673. PMCID: PMC8796987
68. Gopalan A, Winn AN, Karter AJ, Laiteerapong N. Racial and Ethnic Differences in Medication Initiation Among Adults Newly Diagnosed with Type 2 Diabetes. J Gen Intern Med. 2023 Mar;38(4):994-1000. PMCID: PMC10039131
69. Holt JM, Spanbauer C, Cusatis R, Winn AN, Talsma A, Asan O, Somai M, Hanson R, Moore J, Makoul G, Crotty BH. Real-world implementation evaluation of an electronic health record-integrated consumer informatics tool that collects patient-generated contextual data. Int J Med Inform. 2022 Sep;165:104810.
70. Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 Oct;175(10):1392-1400. PMCID: PMC10155215
71. Holt JM, Cusatis R, Mortensen N, Wolfrath N, Hyun N, Winn AN, Brown SA, Somai MM, Crotty BH. Twenty-first century house calls: a survey of ambulatory care providers to inform organisational telehealth strategy. BMJ Health Care Inform. 2022 Dec;29(1). PMCID: PMC9791455
72. Check DK, Baggett CD, Kim K, Merlin JS, Oeffinger KC, Winn AN, Roberts MC, Robinson T, Dinan MA. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. Support Care Cancer. 2022 Dec;30(12):9781-9791.
73. Neuner JM, Fergestrom N, Pezzin LE, Laud PW, Ruddy KJ, Winn AN. Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer. Breast Cancer Res Treat. 2023 Jan;197(1):223-233.
74. Winn A, Basu A, Ramsey SD. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America. Pharmacoecon Open. 2023 Mar;7(2):313-320. PMCID: PMC10043085
75. Centor RM, Laiteerapong N, Winn AN. Web Exclusive. Annals On Call - First-Line Drug Therapy for Type 2 Diabetes. Ann Intern Med. 2023 Feb;176(2):eA220004.
76. Laiteerapong N, Alexander J, Philipson L, Winn AN, Huang ES. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 Apr;176(4):eL230007.
 
Editorials, Letters to Editor, Other
1. Winn AN, Dusetzina SB. More evidence on the limited impact of state oral oncology parity laws. Cancer. 2019 Feb 01;125(3):335-336. PMCID: PMC6361375
2. Winn AN, Neuner JM. Making Sure We Don't Forget the Basics When Using Machine Learning. J Natl Cancer Inst. 2019 Jun 01;111(6):529-530.
3. Winn AN, Keating NL, Dusetzina SB. Reply to E. Ritchie et al. J Clin Oncol. 2017 May 20;35(15):1745-1746.
4. Check DK, Winn AN, Fergestrom N, Reeder-Hayes KE, Neuner JM, Roberts AW. Response to Strassels and Durham. J Natl Cancer Inst. 2020 Dec 14;112(12):1280. PMCID: PMC7735774